We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
RB is the global leading consumer health, hygiene and home company. Driven by a pu...
RB is the global leading consumer health, hygie...
Hera Health Solutions is a pharmaceutical device company based in Memphis, Tenness...
Hera Health Solutions is a pharmaceutical devic...
KalVista is a pharmaceutical company focused on the discovery, development and com...
KalVista is a pharmaceutical company focused on...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our ...
Since our foundation in Dublin, Ireland in 1990...
PhaseBio is a clinical-stage biopharmaceutical company focused on the development ...
PhaseBio is a clinical-stage biopharmaceutical ...
At Insmed we are on a mission to transform the lives of patients battling serious ...
At Insmed we are on a mission to transform the ...
Join the National Investor Network and get the latest information with your interests in mind.